Which has grown faster, FEMY or SNOA?

Over the past five years, FEMY grew revenue faster — FEMY at a 12.97% CAGR versus SNOA at 5.79%.

How have FEMY and SNOA total returns compared?

Over the past 5 years, FEMY delivered -57.27% and SNOA delivered -59.29% annualized total return. Past performance doesn't predict future results.

Femasys Inc. (FEMY) vs Sonoma Pharmaceuticals, Inc. (SNOA)

A side-by-side comparison of Femasys Inc. and Sonoma Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

FEMY

Femasys Inc.

$6M

$2.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SNOA

Sonoma Pharmaceuticals, Inc.

$6M

$1.23HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — FEMY vs SNOA

growth of $100 · dividends reinvested · last 5y

FEMY -99.2% (-61.5%/yr)SNOA -99.2% (-62.0%/yr)FEMY compounded faster over this window

FEMY SNOA

FEMY vs SNOA: by the numbers

•FEMY is the larger company ($6M vs $6M market cap).
•Both run net losses; SNOA's is the smaller (-10.33% vs -534.27% net margin).
•FEMY grew revenue faster over the past five years (12.97% vs 5.79% CAGR).

Metrics side by side

Valuation

Metric	FEMY	SNOA
P/S ratio	2.73	0.27
P/B ratio	1.56	0.89

Profitability

Metric	FEMY	SNOA
Gross margin	61.96%	38.91%
Operating margin	-763.90%	-6.41%
Net margin	-534.27%	-10.33%
ROE	-304.78%	-34.33%
ROIC	-209.05%	-10.98%

Growth (annualized)

Metric	FEMY	SNOA
Revenue CAGR (5Y)	12.97%	5.79%
Total return CAGR (5Y)	-57.27%	-59.29%

Frequently asked

Which has grown faster, FEMY or SNOA?: Over the past five years, FEMY grew revenue faster — FEMY at a 12.97% CAGR versus SNOA at 5.79%.
How have FEMY and SNOA total returns compared?: Over the past 5 years, FEMY delivered -57.27% and SNOA delivered -59.29% annualized total return. Past performance doesn't predict future results.

Go deeper

Full FEMY analysis Full SNOA analysis Interactive comparison tool

Dig into the metrics

Femasys ROE Sonoma Pharmaceuticals ROE Femasys operating margin Sonoma Pharmaceuticals operating margin Femasys revenue growth Sonoma Pharmaceuticals revenue growth Femasys free cash flow Sonoma Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.